Physician profile
Christopher Jordan Gee
NPI 1831372499
$2,732.09
in general payments reported to CMS, 2019-2025
18 companies · $790 in 2025
The $790 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $112 · 2021: $161 · 2022: $206 · 2023: $627 · 2024: $713 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,001 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,001.28 |
| Education | $129.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $747.05 | 2019-2025 | Eylea Hd, Eylea, Evkeeza |
| Genentech USA, INC. | $629.75 | 2019-2025 | Vabysmo, Lucentis |
| Abbvie INC. | $273.16 | 2022-2025 | |
| Apellis Pharmaceuticals, INC. | $154.36 | 2023-2024 | Syfovre |
| Astellas Pharma US INC | $154.22 | 2023-2025 | Izervay |
| Astellas Pharma Global Development | $152.32 | 2024-2025 | Izervay |
| Immunocore Limited | $101.64 | 2024-2025 | Kimmtrak |
| Alimera Sciences, INC. | $87.43 | 2020-2024 | Yutiq, Iluvien |
| Eyepoint US, INC. | $70.32 | 2020-2021 | |
| Biogen, INC. | $69.52 | 2022-2023 | |
| Lumibird Medical INC. | $59.86 | 2025 | |
| Allergan, INC. | $56.41 | 2020-2021 | |
| Neurotech Pharmaceuticals, INC. | $44.37 | 2025 | |
| Novartis Pharmaceuticals Corporation | $36.16 | 2019-2020 | |
| Cardinal Health 108 LLC | $31.28 | 2023-2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $23.41 | 2024 | Quviviq |
| Coherus Oncology, INC. | $21.41 | 2023 | |
| Harrow Eye, LLC | $19.42 | 2025 | Triesence |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Gee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.